AIA
PTLA

Affinity Investment Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Affinity Investment Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-9,575
Closed -$226K – 179
2016
Q2 		$226K Buy
+9,575
New +$236K 0.02% 149

Other funds holding PTLA

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Affinity Investment Advisors's PTLA Position: Q3 2016 in Review

Affinity Investment Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2016, closing a stake of 9,575 shares — an estimated $226K sold.

Affinity Investment Advisors first reported a position in PTLA in Q2 2016 and held it in 1 quarter. The position peaked at $226K in Q2 2016. 151 funds tracked by Wall St. Rank hold PTLA as of Q3 2016.

  • Affinity Investment Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Affinity Investment Advisors sold 9,575 Portola Pharmaceuticals, Inc. shares in Q3 2016, an estimated $226K.
  • Affinity Investment Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Affinity Investment Advisors's Portola Pharmaceuticals, Inc. position peaked at $226K in Q2 2016.
  • 151 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2016.

Based on Affinity Investment Advisors's 13F filing for Q3 2016, filed 7 Nov 2016.